ROLE OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN MANAGING OBESITY AND TYPE 2 DIABETES MELLITUS

Ms. Sugapriya[1], Mr. Suryaprakash, Ms. Divya, Mr. Santhosh

B.Pharm Final Year, Department of Pharmacy Practice, The Erode College of Pharmacy, Erode-638112, Tamil Nadu, India

Guide: Dr. Pasupathi , Department of Pharmacy Practice, The Erode College of Pharmacy erode, The Tamil Nadu Dr. M.G.R. Medical University, Chennai

ABSTRACT

Type 2 diabetes mellitus and obesity have emerged as interconnected global epidemics, often termed "diabesity". More than 90% of newly diagnosed T2DM patients are overweight or obese, highlighting the metabolic link between excess adiposity and glucose dysregulation. While lifestyle modification remains foundational, many patients require pharmacotherapy. Sodium-glucose co-transporter 2 inhibitors represent a novel class of antidiabetic agents that address both hyperglycemia and weight gain through an insulin-independent mechanism. By blocking renal glucose reabsorption, these drugs promote urinary glucose excretion, resulting in sustained caloric loss and 2-4% body weight reduction. Clinical trials have additionally demonstrated cardiovascular and renal protective effects, making SGLT2 inhibitors particularly beneficial for obese T2DM patients with high cardiometabolic risk. This review explores the pathophysiological basis of obesity-driven T2DM, the pharmacology of SGLT2 inhibitors, their clinical efficacy in weight management, comparative data with other agents, and the pharmacist's role in patient education.{1}

Keywords: SGLT2 inhibitors, obesity, type 2 diabetes, diabesity, weight loss, cardiovascular outcomes.

1. INTRODUCTION

The prevalence of obesity has tripled worldwide since 1975, with WHO estimating 1.9 billion overweight adults and 650 million with obesity as of recent global data. This epidemic has driven a parallel rise in type 2 diabetes mellitus, a metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. The coexistence of these conditions is so frequent that clinicians coined the term "diabesity" to emphasize their pathophysiological overlap.

In newly diagnosed T2DM cases, over 90% of individuals carry excess body weight. Adipose tissue, particularly visceral fat deposited around abdominal organs, acts as an active endocrine organ. It releases free fatty acids, tumor necrosis factor-alpha, interleukin-6, and adipokines like leptin and resistin. These mediators disrupt insulin receptor signaling in muscle and liver, reduce glucose uptake, and impair pancreatic insulin secretion. The net result is hyperglycemia and eventual diabetes onset.{2}

Not all individuals with obesity develop T2DM, indicating contributions from genetic predisposition, duration of obesity, fat distribution patterns, and lifestyle behaviors. However, central or abdominal obesity remains the strongest predictor of insulin resistance. This is especially relevant for Asian populations who develop T2DM at BMI values 3-5 kg/m² lower than Caucasians due to higher visceral fat and lower skeletal muscle mass. Hence, WHO and IDF recommend lower BMI cut-offs of 23 kg/m² for overweight and 25 kg/m² for obesity in Asians.

The cardiometabolic consequences extend beyond glucose control. Obesity-associated dyslipidemia with elevated triglycerides and low HDL, combined with hypertension, accelerates atherosclerosis. Cardiovascular disease accounts for two-thirds of mortality in T2DM patients. Chronic low-grade inflammation and oxidative stress further damage endothelial function, worsening microvascular and macrovascular complications.{3}

2. PATHOPHYSIOLOGY: LINKING OBESITY TO T2DM

The metabolic cascade begins when energy intake exceeds expenditure over prolonged periods. Excess calories are stored as triglycerides in adipocytes. As fat stores expand, adipocytes become hypertrophic and hypoxic, triggering macrophage infiltration. These immune cells release inflammatory cytokines that induce systemic insulin resistance.

Visceral adipocytes are metabolically more active than subcutaneous fat. They drain directly into the portal circulation, delivering high concentrations of free fatty acids to the liver. This promotes hepatic gluconeogenesis, VLDL synthesis, and ectopic fat deposition in muscle and pancreas - a process called lipotoxicity. Lipotoxicity damages beta-cells, reducing their capacity to compensate for insulin resistance.{4}

Leptin resistance is another key factor. While obese individuals have high leptin levels, their hypothalamus becomes resistant to its appetite-suppressing effects. This perpetuates overeating and weight gain. Adiponectin, an insulin-sensitizing adipokine, paradoxically decreases in obesity, further worsening metabolic health.{5}

3. MANAGEMENT PARADIGM IN DIABESITY

Current guidelines emphasize a patient-centered approach targeting both glucose control and weight reduction. The American Diabetes Association recommends at least 5% weight loss to achieve clinically meaningful improvements in HbA1c, blood pressure, and lipids. However, maintaining weight loss through diet and exercise alone is challenging, with most patients regaining weight within 3-5 years.

Pharmacotherapy becomes necessary when lifestyle changes prove insufficient. Traditional antidiabetic drugs like insulin, sulfonylureas, and thiazolidinediones often cause weight gain, creating a therapeutic dilemma. This limitation spurred development of weight-neutral or weight-reducing agents. Among these, SGLT2 inhibitors and GLP-1 receptor agonists have transformed management by addressing both glycemia and adiposity.{6}

4. PHARMACOLOGY OF SGLT2 INHIBITORS

The kidneys filter approximately 180 g of glucose daily. Under normal conditions, 90% is reabsorbed in the proximal tubule by SGLT2, while SGLT1 reabsorbs the remaining 10%. In T2DM, this reabsorption capacity increases, contributing to hyperglycemia.

SGLT2 inhibitors are competitive, reversible blockers of this transporter. By inhibiting glucose reabsorption, they induce glycosuria of 60-100 g glucose per day. This equals a caloric loss of 240-400 kcal daily, independent of insulin action. Consequently, the glucose-lowering effect persists even in advanced diabetes with severe beta-cell failure.

Common agents include empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin. They are orally administered once daily and do not require dose adjustment based on meal timing. The natriuretic effect from glucose-linked sodium excretion also explains their blood pressure lowering action.{7}

5. WEIGHT LOSS MECHANISM AND BODY COMPOSITION EFFECTS

The primary driver of weight loss is caloric wasting through urine. Unlike appetite suppressants, SGLT2 inhibitors do not alter hunger hormones directly. The daily glucose loss creates a mild negative energy balance that accumulates over months.{8}

Clinical trials consistently report 2-4% reduction in total body weight within 6-12 months. Importantly, this weight loss is sustained for 4+ years in long-term studies like EMPA-REG EXTEND. Imaging studies using DEXA and MRI reveal that >70% of weight lost comes from fat mass, not lean mass. Both visceral adipose tissue and subcutaneous fat decrease, improving waist circumference and hepatic steatosis.

This preferential fat loss improves insulin sensitivity and reduces inflammatory burden. The diuretic effect from osmotic diuresis also reduces plasma volume and blood pressure, adding cardiovascular benefit.{9}

6. CLINICAL EFFICACY IN T2DM PATIENTS

6.1 Glycemic Control

As monotherapy, SGLT2 inhibitors reduce HbA1c by 0.5-1.0%. The effect is additive when combined with metformin, DPP-4 inhibitors, or insulin. Because the mechanism is glucose-dependent, risk of hypoglycemia is low unless combined with insulin or sulfonylureas.{10}

6.2 Cardiovascular Outcomes

Landmark trials reshaped treatment goals. EMPA-REG OUTCOME showed empagliflozin reduced cardiovascular death by 38% in high-risk patients. CANVAS program with canagliflozin and DECLARE-TIMI 58 with dapagliflozin confirmed reduced hospitalization for heart failure by 30-35%. These benefits appear independent of HbA1c reduction, suggesting pleiotropic effects on cardiac metabolism, preload, and afterload.{11}

6.3 Renal Protection

SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback. DAPA-CKD and CREDENCE trials demonstrated 30-40% reduction in progression to end-stage renal disease. This renal protection extends to patients with and without diabetes.{12}

7. COMPARISON WITH GLP-1 RECEPTOR AGONISTS

GLP-1 RAs like semaglutide and liraglutide mimic incretin hormones to increase insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite. They typically achieve 5-15% weight loss, greater than SGLT2 inhibitors.

However, GLP-1 RAs are injectable and cause more gastrointestinal side effects like nausea and vomiting. SGLT2 inhibitors are oral, better tolerated, and offer superior heart failure and renal benefits. Combination therapy is emerging as a powerful strategy - GLP-1 RA reduces caloric intake while SGLT2 inhibitor increases caloric excretion, producing additive weight and glycemic effects with minimal hypoglycemia risk.{13}

8. ADVERSE EFFECTS AND CONTRAINDICATIONS

The most common adverse effect is genital mycotic infection due to urinary glucose, occurring in 5-10% of patients, more in women. Urinary tract infections and volume depletion may occur, especially in elderly patients on diuretics.

Rare but serious risks include euglycemic diabetic ketoacidosis, Fournier's gangrene, and lower limb amputation with canagliflozin. These drugs are contraindicated in type 1 diabetes, patients with eGFR <30 mL/min/1.73m², and during pregnancy.{15}

9. ROLE OF PHARMACIST IN DIABESITY MANAGEMENT

Pharmacists are uniquely positioned for early intervention. Using ADA risk test, they can screen overweight individuals for prediabetes. Patient counseling should focus on:

1. Self-management education: Teaching glucose monitoring, medication adherence, and recognition of hypoglycemia/ketoacidosis symptoms

2. Nutritional guidance: 500-750 kcal deficit diet, Mediterranean/DASH patterns, meal planning strategies

3. *Physical activity: 150 min/week moderate aerobic exercise + 2-3 days resistance training

4. Behavioral support: Motivational interviewing, stress management, CBT for emotional eating

5. Medication therapy management: Selecting SGLT2 inhibitors for obese patients with CV risk, monitoring for side effects, and ensuring adherence

Community pharmacists can bridge gaps in primary care by providing accessible follow-up and lifestyle coaching.{15}

10. FUTURE PERSPECTIVES

Monotherapy with SGLT2 inhibitors produces modest weight loss insufficient for severe obesity. Research is exploring higher doses, but glucosuric effect plateaus once blood glucose normalizes.{16}

Combination pharmacotherapy appears more promising. Pairing SGLT2 inhibitors with appetite-reducing agents like GLP-1 RAs or phentermine/topiramate may counteract compensatory hyperphagia triggered by caloric loss. Triple therapy with metformin + SGLT2 inhibitor + GLP-1 RA is gaining acceptance for patients needing both glycemic control and substantial weight loss.{17}

Bariatric surgery remains the most effective intervention for BMI >35 kg/m² with T2DM, achieving 15-30% weight loss and diabetes remission in many cases. However, pharmacotherapy offers a less invasive option for patients not eligible or willing for surgery.{18}

11. CONCLUSION

Obesity and T2DM form a vicious cycle that drives global morbidity and mortality. SGLT2 inhibitors break this cycle by targeting both conditions simultaneously through insulin-independent urinary glucose excretion. Their proven benefits on weight, cardiovascular outcomes, and renal protection position them as first-line therapy for obese T2DM patients with cardiometabolic risk.{19}

Successful management demands integration of pharmacotherapy with intensive lifestyle modification and psychological support. Pharmacists, as accessible healthcare providers, play a critical role in education, monitoring, and promoting adherence. Future research on combination strategies and precision medicine approaches will further refine treatment for the growing “diabesity” population.{20}

REFERENCES

1. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95. doi:10.2337/db09-9028

2. Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682-91. doi:10.1111/ijcp.12440

3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875-80. doi:10.1038/nature05487

4. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-94. doi:10.1152/physrev.00055.2009

5. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502. doi:10.1038/nrendo.2012.69

6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720

7. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. doi:10.1056/NEJMoa1611925

8. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57. doi:10.1056/NEJMoa1812389

9. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with obesity: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care. 2012;35(7):1473-6. doi:10.2337/dc11-2260

10. Fadini GP, Avogaro A. SGLT2 inhibitors and body composition: a missing link to cardiovascular protection. Diabetes Obes Metab. 2018;20(12):2743-50. doi:10.1111/dom.13468

11. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356-63. doi:10.2337/dc17-1096

12. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-306. doi:10.1056/NEJMoa1811744

13. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303

14. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54. doi:10.1056/NEJMoa1212914

15. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation; 2021.

16. World Health Organization. Obesity and overweight. WHO Fact Sheet No. 311. Geneva: WHO; 2021.

17. Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes: the VERIFY randomized trial. Lancet Diabetes Endocrinol. 2019;7(3):167-75. doi:10.1016/S2213-8587(18)30310-3

18. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2018;61(12):2461-98. doi:10.1007/s00125-018-4729-5

19. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and the potential of incretin-based therapies. Diabetologia. 2009;52(9):1767-79. doi:10.1007/s00125-009-1426-9

20. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-62. doi:10.1210/jc.2014-3415